How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Nasdaq Dividend History provides straightforward stock’s historical dividends data. Dividend payout record can be used to gauge the company's long-term performance when analyzing individual stocks.

Anthropic’s Claude agents outperformed human researchers and produced “alien science,” raising new questions about AI ...

在过去几年中，数据基础设施的演进始终围绕一个核心问题展开：如何更快地分析数据？ 但进入 2026 年，这个问题正在被重新定义。随着 AI 应用的爆发式增长，数据系统不再只是分析工具，而逐渐成为 智能系统的一部分。数据不再只是被查询，而是被 Agent ...

但进入 2026 年，这个问题正在被重新定义。随着 AI 应用的爆发式增长，数据系统不再只是分析工具，而逐渐成为 智能系统的一部分。数据不再只是被查询，而是被 Agent 调用、被模型理解、被系统实时消费。